Guideline Production Process at a Glance ................................................................. 4

1. Introduction ........................................................................................................... 5
   1.1 Background ........................................................................................................ 5
   1.2 Aims and objectives of the Society in relation to Guideline production .......... 5
   1.3 General principles for BTS Guidelines: AGREE Criteria .............................. 5

2. Initiation of the Guideline production process ...................................................... 6
   2.1 Role of the Standards of Care Committee ...................................................... 6
   2.2 Definition of a Guideline ................................................................................. 6
   2.3 Process for identifying a topic for a Guideline ............................................... 7

3. Composition of Guideline Development Groups (GDG) ...................................... 8
   3.1 Process for selection of Guideline Development Group (GDG) members ....... 8
   3.2 Patient/carer representatives (patient/carer Guideline members) ................. 9
   3.3 Declarations of interest (DoI) ......................................................................... 10
   3.4 Stakeholder input ............................................................................................ 11
   3.5 Training for Guideline Development Group (GDG) members ....................... 11
   3.6 Confirmation of authorship/membership of writing group ......................... 11

4. Guideline Production ............................................................................................ 12
   4.1 Timetable ......................................................................................................... 12
   4.2 Methodology ................................................................................................... 12
   4.3 Defining the scope of the Guideline ................................................................. 13
   4.4 Defining PICO questions; developing search strategies .................................. 13
   4.5 Reviewing the evidence .................................................................................. 15
   4.6 Meta-analysis .................................................................................................. 16
   4.7 GRADE-ing the evidence ............................................................................... 17
   4.8 Formulating and GRADE-ing recommendations ........................................... 18
   4.9 Drafting the Guideline .................................................................................... 20
   4.10 Public consultation and peer review/approval by SOCC ............................ 21
   4.11 Publication/Dissemination ............................................................................ 22


6. Production of Joint Guidelines ............................................................................ 24

References ............................................................................................................... 26

Appendix 1 Appraisal of Guidelines for Research and Evaluation AGREE II .......... 27
Appendix 2 Standards of Care Committee Constitution ........................................... 29
Appendix 3 BTS Guidelines – Topic Proposals ......................................................... 34
Appendix 4 Information on BTS Guidelines ............................................................. 35
Appendix 5 Role Description: Guideline Development Group co-chairs and members 37
Appendix 6 GRADE – relative importance of outcomes ........................................... 39
Appendix 7 BTS Guideline protocol template ........................................................... 40
Appendix 8 Literature search and literature management ........................................... 42
## Guideline Production Process at a Glance

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New guideline topic proposals</strong></td>
<td>Topic selection with reference to BTS strategic objectives (<a href="#">Section 2.3 Process for identifying a topic for a Guideline</a>)</td>
</tr>
<tr>
<td><strong>Call for applications for co-chairs of new GDG</strong></td>
<td>Open recruitment, led by SOCC (<a href="#">Item 3.1.1</a>)</td>
</tr>
<tr>
<td><strong>Open recruitment of all other GDG members</strong></td>
<td>To include trainees (50%), allied health professionals and lay representatives (<a href="#">Item 3.1.3</a>). All members to complete BTS Declarations of Interest forms (<a href="#">Section 3.3 Declarations of interest (DoI)</a>).</td>
</tr>
<tr>
<td><strong>Development of the scope</strong></td>
<td>To be presented to SOCC for approval (<a href="#">Section 4.3 Defining the scope of the Guideline</a>).</td>
</tr>
<tr>
<td><strong>Development of the PICO questions</strong></td>
<td>Clinical questions and outcomes defined for the guideline structure and literature search (<a href="#">4.4 Defining PICO questions; developing search strategies</a>).</td>
</tr>
<tr>
<td><strong>Comprehensive literature search</strong></td>
<td>Completed by University of York.</td>
</tr>
<tr>
<td><strong>Initial screen of abstracts</strong></td>
<td>Completed by co-chairs (<a href="#">Item 4.5.2</a>).</td>
</tr>
<tr>
<td><strong>Full systematic review of the literature</strong></td>
<td>Group members work in small groups to critically appraise relevant papers (<a href="#">4.5 Reviewing the evidence</a>).</td>
</tr>
<tr>
<td><strong>Meta-analysis</strong></td>
<td>Relevant study results statistically pooled into a single result (<a href="#">4.6 Meta-analysis</a>).</td>
</tr>
<tr>
<td><strong>Assessment of the quality of the evidence</strong></td>
<td>Quality of the evidence graded using GRADE methodology (<a href="#">4.7 GRADE-ing the evidence</a>).</td>
</tr>
<tr>
<td><strong>Formulation and GRADE-ing of the recommendations</strong></td>
<td>Recommendations graded as ‘Strong’ or ‘Conditional’ based on the GRADED quality of evidence assessment (<a href="#">4.8 Formulating and GRADE-ing recommendations</a>).</td>
</tr>
<tr>
<td><strong>Full group meeting to discuss findings from evidence review</strong></td>
<td>Co-chairs to create first full draft.</td>
</tr>
<tr>
<td><strong>Presentation of draft to SOCC to seek permission for public consultation</strong></td>
<td>4-6 week period of open public consultation on BTS website. To include Thorax peer reviewers (<a href="#">Appendix 14 BTS Guidelines and Thorax: Production Process</a>). Guideline development group to amend draft in light of public consultation.</td>
</tr>
<tr>
<td><strong>Amended draft to SOCC for final approval</strong></td>
<td>Submission to <strong>Thorax</strong>. Submission to the Thorax Editor-in-chief (<a href="#">Appendix 14 BTS Guidelines and Thorax: Production Process</a>).</td>
</tr>
<tr>
<td><strong>Quality improvement activities</strong></td>
<td>Communication across BTS Committees to ensure the key messages of the guideline are disseminated widely and supported by appropriate resources.</td>
</tr>
</tbody>
</table>
1. Introduction

1.1 Background

1.1.1 The British Thoracic Society (BTS) has been at the forefront of the production of Guidelines for best clinical practice in respiratory medicine since the Society was established over 30 years ago. Over the past 5 years, the methodology for the production of evidence-based Guidelines has evolved considerably and the purpose of the current document is to set out in detail the policy for BTS Guidelines and the procedures for production and review.

1.1.2 BTS Guidelines are intended as an aid to clinical judgement. Guidelines cannot provide the answers to every clinical question and the ultimate decision about a particular clinical procedure, or treatment will always depend on the patient’s condition, circumstances and wishes and the clinical judgement of the healthcare team.

1.1.3 This document has been developed to set out the policies, principles and processes that should be followed in the development of a BTS Guideline. While the document aims to be as instructive as possible, it cannot cover, in detail, every possible issue that may arise during the course of BTS Guideline development. Issues that may arise during the work of a Guideline Group, that are not covered in this document, should be brought to the attention of the Chair of Standards of Care Committee for advice and guidance via the BTS Deputy Chief Executive, or the BTS Clinical Guideline and Quality Standards Programme Manager.

1.1.4 Guidelines published before early 2019 followed the SIGN methodology, as outlined in the 2016 BTS Manual for Guideline Production. In 2014, the BTS Board and the Standards of Care Committee approved a proposal for the Society to move from SIGN to GRADE methodology for all new Guidelines commissioned from 2015.

1.1.5 The 2019 Manual is an update of the 2018 Manual, which was informed by a number of sources of information, including the SIGN 50 Guideline Developer’s Handbook [1], the NICE Accreditation [2] process, input from a range of experts in the field of Guideline development (the National Guideline Centre (NGC) and the Royal College of Occupational Therapists (RCOT)) [5] and the BTS GRADE pilot Guideline group. This advice was gratefully acknowledged. The 2019 Manual cross refers to the comprehensive materials now available for BTS Guideline Groups to support the development of BTS Guidelines from 2019 onwards.

1.2 Aims and objectives of the Society in relation to Guideline production

1.2.1 BTS’ main charitable objective is to improve the care of people with respiratory and associated disorders; and the production of Guidelines that promote optimum standards of care is key to the achievement of this objective.

1.2.2 BTS Guideline production is the responsibility of the BTS Standards of Care Committee (SOCC).

1.3 General principles for BTS Guidelines: AGREE Criteria

1.3.1 BTS Guidelines are produced by Guideline Groups selected, and approved, by the BTS SOCC, with advice from the BTS network of Specialist Advisory Groups (SAGs). The work of Guideline Groups is supported by BTS Head Office staff. The Society does not seek, or accept, external funding for the production of its guidance.
1.3.2 BTS Guidelines are based on the best available evidence and should adhere to the AGREE II Instrument (http://www.agreetrust.org/resource-centre/ – see Appendix 1 Appraisal of Guidelines for Research and Evaluation AGREE II).

2. Initiation of the Guideline production process

2.1 Role of the Standards of Care Committee

2.1.1 The Standards of Care Committee (SOCC) is one of the standing Committees of the Society and has the following remit:

- Primarily, **Guideline development**. This involves the development and maintenance of robust systems for the production of the Society’s own Guidelines, from assessing the need for a Guideline, to the submission for publication, in line with NHS Evidence Accreditation criteria. The scope of this work will involve Guidelines on specific diseases, specific procedures and on processes of care, plus advice about key messages for dissemination, associated audit tool(s) and patient information.

- Production of **Quality Standards**, based on BTS Guidelines, which aim to provide clinicians, commissioners, planners and patients with a guide to the standards of care that patients with a particular disease/condition should expect, together with measurable markers of good practice.

- Production of **Clinical Statements**, which will be commissioned by the Committee and produced according to the agreed procedures.

Additionally, the Committee will identify research questions arising from Guideline development work and refer these directly to the NIHR Respiratory Specialty Group.

2.1.2 The Constitution of the Committee (see Appendix 2 Standards of Care Committee Constitution) sets out the membership, remit and mode of operation of the Committee.

2.1.3 The Chair of the Committee is a Trustee of the Society and sits on the BTS Board.

2.1.4 The BTS Deputy Chief Executive is the secretary to the Standards of Care Committee.

2.2 Definition of a Guideline

2.2.1 Guideline definition: "Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances." [3]

2.2.2 The Society requires that its Guidelines are based on the best possible evidence, but it recognises that in some areas, evidence may be sparse, or of poor quality. When developing guidance in areas where the evidence base is weak, it is important to ensure that robust methodology is used. Guidance on these topics is often much needed and can highlight areas where further research is required.
2.3 Process for identifying a topic for a Guideline

2.3.1 The SOCC is responsible for selecting topics for new BTS Guidelines. The commissioning process is led by the SOCC and the Chair is able seek advice from the BTS Board on future Guideline topics as necessary, to ensure alignment with the Society’s overall strategic objectives.

2.3.2 Guideline topic proposals are welcomed from BTS members, chairs of BTS SAGs, stakeholder organisations and individuals at any point. Proposals are usually considered at one SOCC meeting per year, although proposals may be presented at any point during the year. The detailed process for generating and considering Guideline proposals is outlined in a separate document (see Appendix 3 BTS Guidelines – Topic Proposals).

2.3.3 For Guidelines concerning children, priorities for paediatric Guideline topics will be developed in consultation with the British Paediatric Respiratory Society (BPRS) via the BPRS representatives on the Standards of Care Committee.

2.3.4 In line with NICE Accreditation, all BTS Guidelines are marked as Valid/In Preparation/In Consultation/Withdrawn/Superseded/Archived on the BTS website. At five years after publication, a Guideline will be marked as ‘Archived’ on the BTS website; the SOCC will regularly review the list of Valid/Archived Guidelines. For topics where new guidance is required, the SOCC will consider whether a new Guideline is commissioned (see Appendix 4 Information on BTS Guidelines). The SOCC may also consider whether a topic proposal is suited to the production of a Clinical Statement.

2.3.5 The SOCC will consider the following factors in the approval process for a new Guideline:

- Are there areas of clinical uncertainty as evidenced by wide variation in practice, or outcomes?
- Is this a condition where effective treatment is proven and where mortality and/or morbidity can be reduced significantly?
- Is this a clinical priority area for BTS, where clinical guidance is lacking (and with a perceived need for guidance) and the area is unlikely to be covered by other Guideline producers (such as NICE)?

2.3.6 The Guideline proposal outline should explicitly include:

- The aim of the Guideline
- A clear description of the intended users of the Guideline
- A clear description of which areas are to be included and excluded from the guidance

2.3.7 The SOCC will normally select up to two proposals at a time to go forward into production (when the timetable allows). Proposals that have not been selected may be resubmitted/reconsidered at a later date. Full details of the process are provided in Appendix 3 BTS Guidelines – Topic Proposals.

2.3.8 The timetable for the production of the Guideline should be set out at the start of the group’s work. In general, production of a full Guideline should be completed within two years from the date that the Group is convened. Progress reports on the work of the group should be provided for each SOCC meeting and GDG co-chairs will be invited to attend SOCC meetings at the following specified points in the production process:

- After formation of the PICO questions, but before the literature search is completed. At this meeting, the co-chairs will present the PICO questions to the SOCC and the format, structure, word count and timescale will be discussed and agreed.
- Approximately one year into the process where progress will be discussed and the co-chairs can raise any potential issues or ask questions of the Committee.
The SOCC will receive regular updates from BTS Head Office staff at each meeting. These may highlight the need for additional advice and assistance. Such intervention may be initiated by the Guideline Development Group (GDG) itself, the SOCC, or BTS Head Office.

2.3.9 The costs to be covered by BTS Head Office for the production of the Guideline should be agreed with the GDG chair/co-chairs before work begins. In general, the following items are included within the budget for Guideline production (in line with BTS policies for reimbursement of expenses):

- Guideline group meeting costs (room hire, refreshments, etc.)
- Travel costs for group members to attend meetings
- Costs of literature searches undertaken by the Centre for Reviews and Dissemination, University of York
- Costs of obtaining copies of papers that cannot otherwise be acquired through group members’ own library access (including reimbursement of librarian costs where agreed in advance with BTS Head Office)
- Costs of production of drawings/figures for inclusion in the final Guideline document
- Training costs
- Dissemination/publicity costs (arrangements to be agreed with BTS Head Office)

3. Composition of Guideline Development Groups (GDG)

3.1 Process for selection of Guideline Development Group (GDG) members

3.1.1 Following SOCC approval of the proposed outline for the Guideline, a formal open invitation for applications for the posts of co-chairs of the GDG is issued via the BTS website and BTS member mailings. It is expected that at least one of the co-chairs would be an expert in the topic and skilled in managing a committee. Co-chairs would then be involved in the appointment of GDG members. A full role description for the co-chairs of the Guideline group is provided in Appendix 5 Role Description: Guideline Development Group co-chairs and members and would be provided to those considering applications for the role of GDG co-chairs.

3.1.2 The co-chairs would be expected to:

- Lead the Guideline development group with support from BTS Head Office
- Facilitate the process of the development within the framework of agreed BTS methodology following the AGREE II criteria
- Ensure equality of input from all GDG members
- Adhere to the Society’s policy for declarations of interest and manage declarations of interest and potential conflicts of interest of group members in line with the stated policy (see 3.3 Declarations of interest (DoI))
- Keep to the scope – manage the ambition of the GDG (noting that this is not a textbook)
- Attend all committee meetings and read meeting papers in advance of meetings
- Encourage constructive debate among all group members during meetings
- Participate in Guideline development training as appropriate
• Work with BTS Head Office staff and group members as required during, and between, meetings to identify key issues, formulate clinical questions for review, review evidence and draft recommendations

• Ensure the Guideline production runs to timetable as far as possible

• Lead the write up of the draft document

• Work with group members and BTS Head Office staff to write and edit drafts of the Guideline

• Lead the group in considering and addressing stakeholder comments on the draft Guideline

• Provide progress reports to the BTS SOCC as required

• Attend three agreed SOCC meetings (at the start of the process, after 12 months and then to present the draft guideline before public consultation)

• Support the dissemination and implementation of the guideline - be a champion for the Guideline after publication and undertake activities to promote its implementation, such as talking at professional conferences and participation in the production of publishing Guideline-related articles, in accordance with BTS policy

3.1.3 Following appointment of the co-chairs, an open selection process to recruit other members of the GDG will be conducted (via the BTS website/member mailings). Each GDG would be expected to have the following core members:

- Consultant members, including individuals working in a District General Hospital

- Specialty Trainees - this provides Specialty Trainees with an opportunity for valuable experience in Guideline preparation and brings the perspective of the Specialty Trainee to the Guideline. It is envisaged that up to half of the members of the GDG will be trainees.

- Allied health professionals (recruited via liaison with appropriate organisations, e.g. the Association of Respiratory Nurse Specialists (ARNS), the Association of Chartered Physiotherapists in Respiratory Care (ACPRC), etc.)

3.1.4 In addition, the group will also include:

- Patient/carer representatives (see 3.2 Patient/carer representatives (patient/carer Guideline members))

- Representatives from other stakeholder organisations as required by the topic concerned.

3.2 Patient/carer representatives (patient/carer Guideline members)

3.2.1 In this context the phrase “patient/carer representative” is used to describe patients, carers, or lay representatives who represent and/or support patients in the voluntary sector. Patient/carer input into Guideline development is important to ensure that the Guideline reflects their needs and concerns and addresses issues that may be overlooked by health care professionals.

3.2.2 Each Guideline Group should include at least two patient/carer representatives. Patient/carer members of a Guideline group can be sought from:

- The BTS Lay Trustees/other patient lay contacts

- The Patient Involvement Unit of the Royal College of Physicians (London)
• The British Lung Foundation, Asthma UK, Cystic Fibrosis Trust, or other organisations that have patient involvement/representation as a main objective
• Via personal contacts of GDG members

3.2.3 Clear guidance is given to each patient/carer member of the Guideline Group regarding their role and responsibilities in the work of the Guideline Group. Briefing material for lay/patient members is available and it is likely that separate meetings with the lay/patient representatives, the BTS Lay trustee and one, or more, members of the Guideline group may be arranged, as required, to ensure that lay/patient involvement is ongoing throughout the Guideline production process. The Group will ensure that patient views and experiences inform its work through:
• The identification of key questions that are informed by issues that matter to patients
• Identification of areas where patients’ preferences and choices are of particular importance within the Guideline
• Assisting with the preparation of any Patient Information literature, which may be required, and identifying sources of further information
• Helping to ensure that the Guideline is sensitively and appropriately worded

3.2.4 While it is not expected that patient/carer members will undertake the specific critical appraisal process for individual clinical questions, patient/carer members will be kept informed at all stages and invited to every meeting of the GDG. While much of the discussion at the meetings will be very clinically focussed, all members of the GDG are expected to use appropriate, and where possible accessible, language.

3.3 Declarations of interest (DoI)

3.3.1 The proposed co-chairs of the GDG must complete a BTS Declaration of Interest (DoI) form. Any potential conflicts of interest will be considered by the BTS Honorary Secretary and the Chair of the SOCC before appointment to the role of co-chair and any work on the Guideline is undertaken. The co-chairs should not have any conflicts of interest in relation to the specific Guideline topic. Each member of the GDG must also complete a BTS DoI form before, or at, the first meeting of the GDG and on an annual basis thereafter for the period that the GDG is active. This is in line with the BTS Policy for Declarations of Interest. Information on the BTS Declaration of Interests can be found in Section 3.3. Declarations of Interest (DoIs) of the ‘BTS and Biomedical Industries Policy 2018’ at [https://www.brit-thoracic.org.uk/about-us/governance-documents-and-policies/](https://www.brit-thoracic.org.uk/about-us/governance-documents-and-policies/)

3.3.2 The Chair of the SOCC and the co-chairs of the GDG have responsibility for scrutinising Declarations submitted by GDG members. GDG members are required to complete a DoI form as part of the annual BTS DoI scheme. Copies of DoI forms for group members will be kept on file at BTS Head Office for the duration of the work of the Guideline Group (and then for the subsequent period of time that the Guideline remains valid). Completed returns for active GDG will be available on the public area of the BTS website, and following publication of the Guideline, DoI forms for each GDG are held on file at BTS Head Office and can be provided on request.

3.3.3 DoI are a standing item at the beginning of each GDG meeting. Members will be asked if any new declarations have arisen and forms can be unlocked by BTS Head Office staff if amendments are required. It is expected that the majority of the GDG will have no conflicts of interest. Should a consensus vote be required for any reason, those with conflicts of interest will be excluded from the process.
3.3.4 A statement should be included in each Guideline when published to confirm that GDG members have adhered to the BTS policy for Declaration of Interests and, where appropriate, specific interests should be declared. An example of such a statement for inclusion in the final Guideline document is given below:

“All members of the Guideline Group made declarations of interest in line with the BTS Policy and further details can be obtained on request from BTS.”

3.4 Stakeholder input

3.4.1 The identification and involvement of stakeholders in the development of BTS Guidelines is crucial. One of the initial tasks for the co-chairs of the GDG is to identify potential stakeholders of the final Guideline. BTS Head Office will invite these organisations to either nominate a representative to participate in the preparation of the Guideline as a formal member of the GDG or nominate a contact to whom information on the draft Guideline can be directed as work progresses. BTS Head Office holds a list of stakeholder organisations and contact with each stakeholder organisation is made through BTS. Correspondence with stakeholder organisations will be undertaken by the BTS Clinical Guideline and Quality Standards Programme Manager on behalf of the GDG co-chairs.

3.4.2 BTS aim to ensure that GDG membership comprises all relevant stakeholders. It is important that some organisations (for example, the Royal College of Physicians (London)) have a representative on each GDG. In other cases, it may be sufficient for the organisation to have the opportunity to comment on the draft Guideline at an early stage (or to provide specialist input when required) rather than for the organisation to have a representative on the GDG.

3.4.3 Prior to its first meeting, the GDG will have the opportunity to confirm the list of relevant stakeholder organisations that will be invited to endorse the Guideline at an early stage in the Guideline development process. The list of stakeholders will be published on the BTS website. Stakeholders include patient, professional, commercial, commissioner and government organisations, as well as individual patients and members of the public. All respondents to the public consultation exercise will be required to declare their role/affiliation on the consultation form.

3.4.4 All stakeholders will be sent a copy of the draft Guideline at, or before, the public consultation stage. All stakeholder organisations will then be sent a copy of the final draft Guideline, prior to publication, with a request to confirm their endorsement of the document.

3.5 Training for Guideline Development Group (GDG) members

3.5.1 It is important for all GDG members to be appropriately trained in the methods to be used for the production of an evidence-based Guideline. Where possible the co-chairs of the GDG should receive training in advance of the other members of the group.

3.5.2 Training sessions are organised by BTS Head Office and will usually take place as part of the first, second and third meeting of the GDG. BTS has developed a series of ‘Guide to creating a BTS Guideline’ Handbooks, which will be available to all GDG members after each training session.

3.6 Confirmation of authorship/membership of writing group

3.6.1 In general, all GDG members are usually named as authors (and would contribute appropriately to the authorship of the Guideline – fulfilling the stated criteria for authorship as appears on the Thorax website). The co-chairs are usually named as first authors (or first and last authors). The proposed
authorship of the Guideline should be discussed as early as possible after the GDG starts work, to ensure that all group members are aware of the contribution required.

The authorship of a BTS Guideline should be given in the following form (the names of the co-chairs are usually listed first alphabetically, followed by all members of the group in alphabetical order), e.g.:

*Dr Brian Jones (co-chair), Dr Alan Smith (co-chair), Mr Clive Black, Dr Doreen Grey...*  

*On behalf of the British Thoracic Society*

The full membership of the GDG should also be listed in a section at the start of the Guideline.

### 4. Guideline Production

#### 4.1 Timetable

4.1.1 The timetable for the production of the Guideline should be set out at the start of the group’s work. In general, production of a full Guideline should be completed within 2 years from the date that the group is convened and updates to existing Guidelines should be completed within 12-18 months. Progress reports on the work of the group should be provided for SOCC meetings, including direct reports and presentations from the Guideline co-chairs at agreed intervals (see 2.3 Process for identifying a topic for a Guideline, Item 2.3.8).

#### 4.2 Methodology


Although primarily designed for preparing Cochrane Reviews, RevMan facilitates the preparation of full Guideline text, risk of bias assessment and data meta-analysis (pooling individual study data together to increase data power and precision), allowing Guideline evidence reviews and data to be stored together in individual RevMan files (one per clinical question).

GRADE is a method used to assess the quality of the evidence and decide whether to recommend an intervention. GRADE ensures that the process is systematic and transparent. GDGs will adopt clearly defined elements of the GRADE system (Grading of Recommendations, Assessment, Development and Evaluation) outlined in Section 4.7 GRADE-ing the evidence. GDGs should note that the system used should adhere to the AGREE II criteria (see Appendix 1 Appraisal of Guidelines for Research and Evaluation AGREE II).

Full training, instruction and support will be provided to all GDG members on all BTS Guideline methodologies.

4.2.2 The Guideline should include clear recommendations and include their GRADE category (‘Strong recommendation’ or ‘Conditional recommendation’). A synopsis of the GRADE-ing categories is included in Section 4.7 GRADE-ing the evidence and 4.8 Formulating and GRADE-ing recommendations. There should also be an explicit link between each recommendation and the supporting evidence.
4.3 Defining the scope of the Guideline

4.3.1 In line with the AGREE II criteria (see Appendix 1 Appraisal of Guidelines for Research and Evaluation AGREE II), each Guideline should explicitly state the clinical questions to be addressed and the patient population/target audience for the Guideline. Areas specifically excluded by the Guideline should also be itemised.

4.3.2 Consideration should be given to palliative care issues and, where appropriate, the document should include a section on end of life issues.

4.3.3 Studies often record side effects, harmful effects and risks of effects of interventions under scrutiny, but these are rarely primary outcome measures. Where evidence permits, these will be balanced against beneficial effects with a view to informing recommendations.

4.4 Defining clinical questions; developing search strategies

4.4.1 BTS Guidelines should be based on a systematic review of the evidence. Systematic review is defined as “an efficient scientific technique to identify and summarise evidence on the effectiveness of interventions and to allow the generalisability and consistency of research findings to be assessed and data inconsistencies to be explored”. [4]

4.4.2 The essential principles of a systematic review should be adhered to and the literature should be:

- Identified according to an explicit search strategy
- Selected according to defined inclusion and exclusion criteria; and
- Evaluated against consistent methodological standards

4.4.3 Where high quality, directly relevant Guidelines exist within the scope of a new Guideline, reference can be made to the existing Guidelines rather than repeating work that has already been completed. However, all such existing Guidelines must be evaluated using the AGREE II instrument, and be shown to have followed an acceptable methodology, before they can be considered for use in this way.

4.4.4 Guideline groups are required to break the Guideline remit down into a series of structured key questions. Each question must use one of question formats below:

**Intervention (PICO)**

- Patients or population to which the question applies
- Intervention (or diagnostic test, exposure, risk factor, etc.) being considered in relation to these patients
- Comparator(s) to be used to compare the effect of the ‘Intervention’ against; and
- Outcome(s) to be used to establish the size of any effect caused by the ‘Intervention’

**Diagnostic (PinGO)**

- Patients or population to which the question applies
- Index test(s) being considered in relation to these patients
- Gold standard being used to compare the effectiveness of the ‘Index test(s)’; and
- Outcome (diagnostic accuracy outcome); or
Prognostic (PERO)

- Patients or population to which the question applies
- Exposure(s) (non-imposable characteristics) being considered in relation to these patients
- Referent, which is/are the opposite of the ‘Exposure(s)’; and
- Outcome(s) to be used to establish the prognostic effect of the ‘Exposure(s)’

It is important that the scope, and all subsequent questions and identified outcomes, is tightly focused. The SOCC will provide advice on this to ensure that the Guideline is achievable in the timescale and that it will be of practical use clinically when published.

4.4.5 The Patients or Population to be covered by the literature searches is largely defined by the presence of the particular condition that the Guideline will cover. It should be made clear at this stage, however, which age groups will be covered and which will be excluded (i.e. if the Guideline covers adults only, or children only, the age range should be specified, e.g. 16 years and over, or up to and including 16). The age range given will be agreed by the GDG for each specific guideline topic.

4.4.6 Consideration should also be given as to whether any ethnic, or social groups have particular needs in relation to the topic under review. Exclusion of any group from the population covered by the Guideline should be identified when setting the key questions and reasons given for their exclusion.

4.4.7 The Intervention(s) (which in this context includes diagnostic tests, risk factors and risk exposure), Index test(s), or Exposure(s) must be specified clearly and precisely. The only exception is in drug therapy where drug classes should be used in preference to specific agents, unless there is a clear reason for focussing on a named agent.

4.4.8 For Intervention (PICO) questions, the GDG need to decide on the Comparator(s), which will be used to compare the Intervention(s) against. Comparators are most often placebo/no treatment, comparison with other therapies, or the existing standard of care.

For Diagnostic (PInGO) questions, the Gold standard must be the best diagnostic test that is available for diagnosing the condition of interest (diagnostic accuracy Outcome).

For Prognostic (PERO) questions, the Referent is always the opposite of the Exposure (e.g. Smoking/Non-smoking).

4.4.9 An Outcome is something that can be measured and the three question types have different types of outcomes:

- A diagnostic (PInGO) outcome is always a ‘Diagnosis of the disease of interest’
- A prognostic (PERO) outcome is always measure of the prognostic effect of the Exposure(s) (e.g. the probability of developing a disease, the probability of responding to a treatment, etc.); and
- An intervention (PICO) outcome is something that can be measured to show the effect of an Intervention. Intervention (PICO) outcomes should always be patient-important and should be GRADE-categorised according to their importance for decision-making (see Appendix 6 GRADE – relative importance of outcomes):
  - Critical
  - Important, but not critical
  - Of limited importance
Only outcomes categorised as ‘Critical’ or ‘Important, but not critical’ should be used in a Guideline PICO question and the number of outcomes for each clinical question should be limited to about four. GDG members should agree on the outcomes for each PICO question when the PICO questions are being developed and before the literature review begins. Examples of patient-important PICO outcomes are reduced morbidity, improved quality of life, reduced infection, etc.

4.4.10 When each question has been defined, a protocol should be set for each question. The protocol is a very detailed version of the review question and includes the PICO, PInGO or PERO, the types of studies to be included in the review, the search plan and the analysis plan. The protocol should always be set before the literature review begins to avoid bias (please see Appendix 7 BTS Guideline Protocol Template).

4.4.11 The PICO/PInGO/PERO questions will then form the basis of the literature search. BTS has a service level agreement with information specialists in York who are able to provide assistance with literature searches and guidance on formulating search strategies including advice on search terms and sources to be consulted such as Medline, US National Guideline Clearing House, Embase and Psychinfo (see Appendix 8 Literature search and literature management).

4.4.12 The literature search must focus on the best available evidence to address each PICO/PInGO/PERO question and should ensure maximum coverage of studies that include:

- Systematic reviews
- Randomised controlled trials
- Observational studies; and
- Diagnostic studies

4.4.13 Details of the search strategies, dates of searches, etc. should be included in the final document (and can also be made available as an accompanying web appendix on publication).

4.5 Reviewing the evidence

4.5.1 The literature search will produce a long list of potential sources of evidence. Each reference must then be assessed to ensure its relevance and validity. GDG members should review the evidence (bearing in mind the AGREE II criteria). Guidance will be provided by BTS Head Office (see Appendix 8 Literature search and literature management).

4.5.2 An initial literature review should be performed to remove all references from the literature search list that are not relevant to the Guideline. This process should be performed by two GDG members (usually the co-chairs) and agreement should be reached on which references to include/exclude.

4.5.3 The abstracts on the revised literature list should then be allocated to each PICO/PInGO/PERO question and identification details of each abstract (per PICO/PInGO/PERO question) should be input into RevMan. Full training and support will be provided by BTS Head Office on inputting data into RevMan.

4.5.4 At least two GDG members should be assigned to each PICO/PInGO/PERO question to ensure that each abstract is being reviewed by at least two people. An initial review of each allocated abstract should be performed to assess the relevance to the PICO/PInGO/PERO question, i.e. does the abstract:

- Include the PICO/PInGO/PERO population(s)?
- Include the PICO intervention(s), the PInGO index test(s) or the PERO exposure(s)?
• Include the PICO/PlnGO/PERO comparator(s), the PlnGO gold standard, or the PERO referent?
• Or, include the PICO/PlnGO/PERO outcome(s)?

For this first review, if the abstract fulfils any of the above criteria, the reference should be included in the next step of the process. The list of included and excluded abstracts should then be agreed between GDG members assigned to the PICO/PlnGO/PERO question. The reason(s) for excluding an abstract at this stage should be recorded to ensure transparency of the process.

4.5.5 Abstracts should not be rejected on the basis of the journal of publication, location of research or location of publication.

4.5.6 Abstract should not be rejected on the date of publication (unless agreed by GDG members and detailed on the Protocol (see Appendix 7 BTS Guideline Protocol Template) before the literature review begins).

4.5.7 Non-English abstracts should be considered, provided there is an English translation available. It would not be usual to provide translations of non-English papers unless a compelling case could be made. The GDG should consult with BTS Head Office if such an issue arises.

4.5.8 GDG members are encouraged to make full use of their NHS/university library resources to obtain full copies of the ‘Included abstract’ papers, remaining within copyright rules at all times. Where GDGs encounter difficulty in obtaining copies of papers, BTS Head Office can offer advice and assistance.

4.5.9 ‘Included abstract’ papers should be divided between GDG members assigned to the PICO/PlnGO/PERO question. Each full paper should be assessed using the following protocol:

Read the LAST section of the INTRODUCTION, this outlines the purpose of the study and outlines what has been done. [6]

ALL papers that address the PICO/PlnGO/PERO question should be ACCEPTED

ALL papers that do not address the PICO/PlnGO/PERO question should be REJECTED

An exception to this can be made if the literature available to answer the PICO/PlnGO/PERO question is limited (i.e. a paper can be included if there is limited supporting literature and the paper addresses some of the PICO/PlnGO/PERO criteria)

4.5.10 Each ACCEPTED paper should be critically appraised and a risk of bias assessment completed for each ACCEPTED paper in RevMan. Full training and support will be provided to all GDG members.

Each critical appraisal should be agreed by all GDG members assigned to the PICO/PlnGO/PERO question, but where there is a difference of opinion on a paper, GDG reviewing groups should endeavour to reach a consensus, or refer to the GDG co-chairs for a final decision.

An ACCEPTED paper can become a REJECTED paper at any time during the critical appraisal process, but if a paper is later rejected, an explanation should be recorded in RevMan.

4.6 Meta-analysis

4.6.1 Meta-analysis is a statistical technique to summarise the results of several studies into a single overall result (a pooled estimate). This increases the power and precision of the estimate of the effect. If there is enough supporting evidence, GDG members should use RevMan to perform meta-analyses on the final ACCEPTED paper study (see Item 4.5.10). Individual meta-analyses should be performed for each PICO and PlnGO outcome PERO question data can take different formats, so there is no
defined method of performing meta-analyses for prognostic review questions. GDG members assigned to a PERO question should consult with the BTS Clinical Guideline and Quality Standards Programme Manager for advice on how to pool the data. Full training and support will be provided by BTS Head Office staff.

4.7 **GRADE-ing the evidence**

4.7.1 When all **ACCEPTED** papers (see Item 4.5.10) have been critically appraised for risk of bias and meta-analyses have been completed, GDG members are required to assess the quality of the evidence using GRADE methodology.

4.7.2 GDG reviewing groups who are assigned to PICO or PERO questions (as defined in Item 4.5.4) will use GRADEprofiler software ([https://grade profiler.software.informer.com/3.6/](https://grade profiler.software.informer.com/3.6/)) to assess the quality of the evidence. One GRADEprofiler file will be created per PICO/PERO question and the quality of the evidence will be assessed per outcome.

GDG reviewing groups who are assigned to a PInGO question (as defined in Item 4.5.4) will use GRADEpro ([https://gradepro.org/](https://gradepro.org/)) to assess the quality of the evidence. GRADEpro is an online program and one GRADEpro project will be created per PInGO question. The quality of the evidence will be assessed per outcome.

For PICO questions, and PERO questions that include meta-analyses, GDG reviewing groups should import their PICO/PERO question RevMan file (containing the risk of bias assessment (see Item 4.5.10) and outcome meta-analyses (see 4.6 Meta-analysis)) into GRADEprofile r to transfer the ‘Summary of Findings’ data from the outcome meta-analyses (see Appendix 9 Example Summary of Findings table).

For PERO questions that do not include meta-analysis data, GDG members should consult with the BTS Clinical Guideline and Quality Standards Programme Manager for advice on inputting the ‘Summary of Findings’ data into GRADEprofiler.

For PInGO questions, the BTS Clinical Guideline and Quality Standards Programme Manager will input the ‘Summary of Findings’ data into GRADEpro.

Full training and support will be provided to all GDG members by BTS Head Office staff.

4.7.3 For each PICO/PInGO/PERO outcome, GDG reviewing groups should decide what the predominant study design is for the studies included in the evidence and input their decision into GRADEprofiler (PICO and PERO questions) or GRADEpro (PInGO questions). Different study types will give an initial GRADE-ing of the evidence (dependent on the question type):

- **PICO**
  - Randomised controlled trial (RCT) = high
  - Observational study = low

- **PInGO**
  - Cross-sectional (cohort type accuracy study) = high
  - Cohort and case-control type studies = moderate
  - Case-control type accuracy study = low

- **PERO**
  - Observational study = high
  - Randomised controlled trial (RCT) = low
4.7.4 GDG members should then GRADE the quality of the evidence. The quality of the evidence should be assessed per outcome (i.e. across the evidence for each PICO/PInGO/PERO outcome) and should consider the level of the following domains: Risk of bias, Inconsistency, Indirectness, Imprecision and Publication Bias. GDG reviewing groups should agree on the GRADE quality of evidence assessments and input the results into GRADEprofiler (PICO and PERO questions) or GRADEpro (PInGO questions). Footnote comments should be provided to ensure transparency and full training will be given to all GDG members.

If there is disagreement between members of a GDG reviewing group, the quality of evidence assessment should be referred to the GDG co-chairs for a final decision.

4.7.5 Full information on upgrading and downgrading Guideline evidence quality is available in the GRADE Handbook (http://gdt.guidelinedevelopment.org/app/handbook/handbook.html).

4.7.6 Following a full GRADE assessment of the PICO/PInGO/PERO question evidence (per outcome), and inputting all appraisal data into GRADEprofiler (PICO and PERO questions) or GRADEpro (PInGO questions), GRADEprofiler, or GRADEpro, will automatically GRADE the quality of the evidence as ‘High’, ‘Moderate’, ‘Low’, or ‘Very Low’ based on the information provided. A description of each GRADE is provided in the table below.

<table>
<thead>
<tr>
<th>GRADE</th>
<th>Definition</th>
<th>Characteristics</th>
<th>Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>High confidence that the true effect is close to the estimated effect</td>
<td>Based on consistent results from high-quality studies (see Item 4.7.3)</td>
<td>Further research is very unlikely to change the estimate of the effect</td>
</tr>
<tr>
<td>Moderate</td>
<td>Moderate confidence that the true effect is close to the estimated effect</td>
<td>Based on high-quality studies where there is evidence of bias, or from studies of moderate quality (see Item 4.7.3)</td>
<td>Further research is likely to have an impact on the estimate of the effect</td>
</tr>
<tr>
<td>Low</td>
<td>Low confidence that the true effect is close to the estimated effect</td>
<td>Based on evidence from low-quality studies, or from high quality studies with several serious limitations (see Item 4.7.3)</td>
<td>Further research is likely to have an important impact</td>
</tr>
<tr>
<td>Very Low</td>
<td>Very low confidence that the true effect is close to the estimated effect</td>
<td>Based on low-quality studies, or expert opinion (see Item 4.7.3)</td>
<td>Estimates of effect are far from certain and more research is needed</td>
</tr>
</tbody>
</table>

4.8 Formulating and GRADE-ing recommendations

4.8.1 When the quality of all evidence per PICO/PInGO/PERO question (i.e. the evidence across all outcomes) has been assessed, and all information has been input into GRADEprofiler (PICO and PERO questions) or GRADEpro (PInGO questions), this is the information should be used to formulate the recommendations.

GRADEprofiler and GRADEpro have a specific tool for developing the recommendations. GDG reviewing groups will make judgement on a series of questions e.g. is the problem a priority, are the
anticipated effects desirable, how substantial are the undesirable effects, what is the certainty of the evidence, etc. and will include information on the research evidence (to be taken from the evidence review/’Support for judgement’). Examples of question formats are shown in Appendix 10 GRADEpro recommendations.

The judgements will be summarised in the ‘SUMMARY OF JUDGEMENTS’ table and will be the basis for deciding the ‘TYPE OF RECOMMENDATION’ (see Appendix 10 GRADEpro recommendations and Item 4.8.2 below).

4.8.2 Guideline recommendations are graded to differentiate between those based on strong evidence and those based on weak evidence. This judgement is made on the basis of an (objective) assessment of the design and quality of each study and a considered judgement on the consistency, clinical relevance and external validity of the whole body of evidence. The GRADE system assigns a recommendation as ‘Strong’ or ‘Conditional’:

<table>
<thead>
<tr>
<th>Strength</th>
<th>Benefits and risks</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong. It is recommended and so “offer”</td>
<td>Benefits appear to outweigh the risks (or vice versa) for the majority of the target group</td>
<td>Most service users would want to, or should receive this intervention</td>
</tr>
<tr>
<td>Conditional. It is suggested and so “consider”</td>
<td>Risks and benefits are more closely balanced, or there is more uncertainty in likely service users’ values and preferences</td>
<td>The service users should be supported to arrive at a decision based on their values and preferences</td>
</tr>
</tbody>
</table>

It should be noted that it is reasonable for GDGs to make strong recommendations based on weak evidence where appropriate. A strong recommendation need not exclusively come from a strong evidence base, but an explanation on why this decision has been made should be provided in the Guideline.

4.8.3 The body of evidence for each PICO/PInGO/PERO question will then be drawn together into a BTS Guideline Support for Judgement Template (see Appendix 11 BTS Guideline Support for Judgement Template) where a draft evidence review, evidence statements, recommendation and, where appropriate, good practice points (GPPs), will be produced.

GPPs are intended to offer short pieces of advice, which may not have an evidence base, but are viewed as essential to good clinical practice. GPPs may arise in a Guideline where the evidence is insufficient to be systematically reviewed, but where there may be a need to guide practice. All GPPs will be arrived at by consensus, based on the clinical experience of the GDG members.

4.8.4 In GRADE-ing the recommendations the GDG should consider the following aspects for considered judgement:

- The volume of the body of evidence for that particular outcome
- The applicability of the obtained evidence to the defined target audience of the Guideline
- The generalisability of the evidence to the target population of the Guideline
- The level of consistency in the evidence obtained to support recommendations
- The implications of recommendations on clinical practice in terms of deliverability

The agreement on recommendations to be included in the Guideline will be reached by consensus among the GDG members. Following production of the final draft Guideline document, the GDG
members will be invited to vote on each recommendation (and GPPs) to indicate approval for each recommendation. The GDG will be expected to confirm at the outset of its work that agreement from 80% of the group would be the threshold for acceptance of any given recommendation/GPPs.

4.8.5 If the GDG feels strongly that they want to make a recommendation even though there is no significant evidence, this should be presented as a ‘Conditional’ recommendation (please see Item 4.8.2) making it clear it is based on very low quality evidence. There should be some evidence of opinion supporting the recommendation from outside the GDG. If no such evidence exists, formal methods should be used to develop a consensus-based recommendation and these methods will be clearly identified as such within the Guideline. The methods used to reach consensus may vary between GDGs; and whatever method is used, it is essential that it is described either in an Annex to the Guideline, or as a supporting document linked to the Guideline on the BTS website. Where there is a lack of evidence on a particular outcome, the GDG should be clear about how a consensus has been reached in formulating a recommendation (for example using the Delphi process). Where areas of uncertainty exist within the evidence, this should be highlighted as appropriate within the Guideline document.

4.8.6 While BTS Guidelines explicitly exclude consideration of cost-benefit analysis, GDGs may include a consideration of cost implications and cost-effectiveness issues where literature exists that is appropriate to the topic. It is expected that the GDGs would discuss potential organisational and financial barriers, which may impact on the implementation of the recommendations.

4.9 Drafting the Guideline

4.9.1 When producing a draft of the Guideline the following structure is suggested:
- Title page listing authors
- Contents page
- Summary of recommendations (to be finalised on completion of the Guideline)
- Introduction (see Item 4.9.2)
- The body of the Guideline, divided into sections and PICO/PInGO/PERO questions as appropriate, with each recommendation clearly identified in bold type and numbered consecutively throughout the document
- Conclusion
- Appendices and list of web appendices
- Figures/Tables
- References

4.9.2 The Introduction should include:
- The aim of the Guideline
- A description of the intended users of the Guideline
- A description of the target patient population
- A clear description of which areas are included and excluded from the guidance
- A description of the methodology used
• A description of the search methodology, the dates of the literature searches and how many papers were considered. The detailed search terms should be included in a Web Appendix
• A statement on when the Guideline should be reviewed/revised – this is normally within 5 years from the date of publication
• A description of the inclusion and exclusion criteria for evidence selection
• A statement on declarations of interest
• A full list of the GDG members and the contributors to each section of the Guideline, noting where individual members have represented other organisations
• A list of stakeholders/endorsing organisations (to be finalised prior to publication)

4.9.3 The following sections are also associated with the Guideline, but are usually provided as web based appendices rather than part of the published document (see Appendix 12 Supporting information):
- Research recommendations
- Audit criteria
- Patient information where appropriate
- Educational material
- Quality Standards (see Appendix 13 BTS Quality Standards and Audits).

4.9.4 GDGs should ensure that the level of evidence is clearly indicated against each evidence statement and that individual references that are included in the evidence summary appear in the accompanying evidence table (as well as in the bibliography). The GRADE of recommendation should be clearly indicated against the recommendation when it appears in the Guideline (see Item 4.8.2). Reference should be included in the Vancouver format (the style used by Thorax) where references are numbered sequentially in the text.

4.9.5 The following paragraph should be inserted at final draft stage:

Healthcare providers need to use clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply recommendations for the management of patients. The recommendations presented here are a guide and may not be appropriate for use in all situations. The guidance provided does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

4.10 Public consultation and peer review/approval by SOCC

4.10.1 The final draft Guideline should be submitted to the Chair of the SOCC for comment and discussion at a meeting of the SOCC. The co-chairs of the GDG will be invited to be present at that meeting. Peer review will be undertaken by SOCC members, who may also invite key expert reviewers to provide comments. The public consultation period takes place immediately after the SOCC meeting provided the Committee has given approval that the draft Guideline is suitable for the consultation process to take place.

4.10.2 The approved draft of the Guideline should usually be placed on the BTS website for open consultation and, if the timing allows, an open meeting should be held at a BTS Summer/Winter meeting. A consultation copy of the document should be sent to all stakeholders requesting their comments by the consultation deadline.
4.10.3 A standard form is used to collect the comments from respondents who are asked to specify if the comments are submitted on behalf of an individual or an organisation. All comments are collated and sent to the co-chairs of the GDG. The actions for each comment are recorded, even if there is no change/action required. All amendments to the draft must have the agreement of the GDG.

4.10.4 At this stage, the editors of Thorax are invited to propose expert reviewers to comment on the draft Guideline as part of the public consultation process. This satisfies the external peer review process for the journal and means that a further peer review process is not required following final approval of the Guideline by the Standards of Care Committee. The consultation copy of the Guideline will be submitted to Thorax via Scholar One to allow the editors to invite peer review through the usual Thorax system. Comments from the Thorax reviewers will be passed through to BTS so that these comments can be addressed alongside all feedback from the consultation process. A separate document outlining the process for the publication of BTS guidelines in Thorax is available and kept under regular review with the editors in chief (see Appendix 14 BTS Guidelines and Thorax: Production Process). It should be noted that when the Guideline is published it is noted as subject to internal Thorax review as the external peer review process has taken place as part of the public consultation stage (see Appendix 14 BTS Guidelines and Thorax: Production Process).

The spreadsheet of comments and associated actions is included in the submission for publication to Thorax to provide evidence of external peer review.

4.10.5 Following the incorporation of comments from the SOCC meeting and the open consultation, the final draft document should be returned to the SOCC for approval. At this point the SOCC may request a further review of the document before approval is given.

4.10.6 When the final draft has been approved, the document should be sent to stakeholders (relevant organisations/Royal Colleges) to request confirmation of endorsement, if applicable.

4.11 Publication/Dissemination

4.11.1 The principles and procedures for publication of the full Guideline/Executive Summary of the Guideline in Thorax are set out in Appendix 14 BTS Guidelines and Thorax: Production Process. An online copy of the full Guideline (and associated web appendices) will be available on the BTS website following publication. Options for alternative publication arrangements should be discussed with the SOCC Chair and BTS Head Office.

4.11.2 BTS Head Office is responsible for liaising with the Thorax Production team regarding the likely timing of publication. BTS Head Office will submit the final manuscript to Thorax via Scholar One and will be the main point of contact with Thorax for production issues. The corresponding authors will be responsible for checking the proofs of the Guideline.

4.11.3 The sequence of events for the publication process is as follows:

- Final draft is considered by the SOCC (at this point a copy of the draft is sent to the Thorax editors for information with an estimate of when the final document is likely to be formally submitted to Thorax)
- When the final draft is approved by the SOCC Chair, BTS Head Office takes responsibility for checking its content (to confirm that all figures/tables and associated documents are available), and confirming with the corresponding authors
- BTS Head office submits the required documents to Thorax via Scholar One (the Thorax manuscript submission system)
- Thorax will communicate with the designated corresponding authors for checking of proofs
- BTS Head Office will provide Thorax with instructions such as authorisation for production of colour figures etc.

- Final proofs signed off by the corresponding author

- BTS Head Office will produce the Full Guideline/Quick Reference Guide/Summary of Recommendations document (as required) for download from the BTS website to coincide with publication (published under BTS ISSN report series)

- A summary of Guideline recommendations will be submitted to BMJ Open Respiratory Research for simultaneous publication on the open access journal website

- Thorax confirms the likely publication date

- On publication, Thorax provides a pdf copy of the document which is placed on the BTS website with the associated full Guideline/Quick Reference Guide/additional documentation

4.11.4 BTS Head Office, in consultation with the co-chairs of the Guideline group and the SOCC chair, will oversee the press and media coverage associated with the publication of the Guideline.

4.11.5 Copies of the Guideline RevMan files, GRADEprofiler files, evidence tables, references and literature search records, together with notes of the GDG meetings, should be held at BTS Head Office.

4.11.6 BTS Head Office will arrange for relevant associated materials (educational documentation, audit tools and patient information) to appear on the BTS website to coincide with the Guideline publication.

4.11.7 BTS Head Office will explore appropriate ways to support the dissemination of the key messages of each Guideline, e.g. the Society may provide open-access educational slides, eLearning modules, short courses and/or symposia at the BTS Winter or Summer Meetings, examples of template documents which support the guideline recommendations, etc.

5. **Process for Review/Updating of Existing Guidelines**

5.1 Guidelines are not routinely updated at a certain time point. Once a Guideline has been published for five years, it will be automatically moved to the online archive on the BTS website with no specific review. Updates to existing topics are viewed as new projects and would not follow on from the original publication. The validity of the proposal would be considered alongside the other proposals (see Appendix 4 Information on BTS Guidelines).

5.2 The BTS website includes a list of published Guidelines with an indication of the status of the document as follows:

- **Valid** Guidelines that have been published within the past five years, or have undergone an ‘Exceptional Review’ by the SOCC and have been deemed ‘Valid’

- **In Preparation** Guidelines in development

- **In Consultation** Guidelines that are available for public consultation

- **Archived** Guidelines that have been published for more than five years. The following text will be included on the relevant webpage:
BTS Guidelines published more than five years ago are marked as archived. The Guideline content/recommendations have not been checked to confirm continued validity at the date of archival and readers should bear in mind that new evidence may have been published since the Guideline was produced.

**Superseded**
Guidelines that are deemed to be no longer valid as a more recent version has been published.

**Withdrawn**
Guidelines that are deemed to no longer be valid but where a revision has not been published (with the date of withdrawal included) (see Appendix 4 Information on BTS Guidelines).

5.3 It is recognised that there may be occasions where an ad-hoc update to a specific aspect of a published Guideline may be required within a short timeframe. The need may arise for additional advice to be made available where a major new piece of evidence that impacts on a guideline recommendation is published. In instances such as these, the Society would take advice from its network of Specialist Advisory Groups (SAGs) on whether an immediate statement is required to be made available on the BTS website (and drawn to the attention of the relevant health care professionals via its communications networks). The Society may also commission and publish a “Clinical Statement” which would provide a review of the current state of the art in a given area of respiratory medicine, together with advice on good practice. Such statements would be commissioned on the expert advice/intelligence gathered by the Society’s SAG network, and produced under the auspices of the Standards of Care Committee.

6. Production of Joint Guidelines

6.1 The Society may be approached by other organisations or group with an invitation to produce a joint Guideline.

6.2 The SOCC will consider proposals for the production of joint Guidelines and will require that the methodology used in the Guideline production process meets the standards required for the production of BTS Guidelines. In such circumstances, the Society would expect to nominate an appropriate proportion of members of the Guideline group (and this could include nomination of a co-chair) and the draft Guideline would be submitted for comment and approval by the BTS Standards of Care Committee in the normal way.

6.3 The British Thoracic Society has a formal agreement with SIGN to produce the British Guideline on the Management of Asthma and, in the case of this Guideline, the SIGN Guideline production procedure is used.

7. BTS representation and endorsement of externally produced Guidelines

7.1 The Society may be invited to nominate a BTS representative to act as a member of another organisation’s Guideline group. The Standards of Care Committee will approve an individual as a BTS representative on a Guideline group provided that:

- The Guideline topic and outline is deemed appropriate
- The Guideline methodology and production process is in line with that used by the Society
• That the nominated representative agrees to provide a brief written report to each meeting of the Standards of Care Committee

• That the final draft Guideline is presented to the SOCC (with the BTS representative in attendance) for approval

7.2 In the case of requests for formal endorsement of another institution’s Guideline, the Society would expect to nominate at least one representative member of the Guideline group and the draft Guideline would be submitted for comment and approval by the BTS Standards of Care Committee in the normal way, before a decision on whether to endorse the Guideline is made (see Item 7.1 above).

BTS June 2019
References


Appendix 1  Appraisal of Guidelines for Research and Evaluation AGREE II


The AGREE II criteria for assessment of guidelines includes judgements about the methods used for developing the guidelines, the content of the final recommendations and the factors linked to their uptake. The AGREE Instrument assesses both the quality of the reporting, and the quality of some aspects of recommendations. It provides an assessment of the predicted validity of a guideline, i.e. the likelihood that it will achieve its intended outcome. It does not assess the impact of a guideline on patients’ outcomes.

The 23 criteria are summarised below:

**Scope and Purpose**

1. The overall objective(s) of the guideline should be described in detail and the expected health benefits from the guideline should be specific to the clinical problem.
2. A detailed description of the health questions covered by the guideline should be provided.
3. There should be a clear description of the target population to be covered by the guideline.

**Stakeholder involvement**

4. The guideline development group should include individuals from all the relevant professional groups.
5. The views and preferences of the target population (patients, public) should be sought.
6. The target users of the guideline should be clearly defined.

**Rigour of development**

7. Systematic methods should be used to search for evidence
8. The criteria for selecting the evidence must be clearly described.
9. The strengths and limitations of the body of evidence should be clearly described.
10. The methods used for formulating the recommendations should also be clearly described.
11. The health benefits, side effects and risks should be considered in formulating the recommendations.
12. There should be an explicit link between the recommendations and the supporting evidence.
13. The guideline should be externally reviewed by experts prior to its publication.
14. A procedure for updating the guideline should be provided.

**Clarity and Presentation**

15. The recommendations should be specific and unambiguous.
16. The different options for management of the condition or health issue should be clearly presented.
17. Key recommendations should be easily identifiable.

**Applicability**

18. The guideline should describe facilitators and barriers to its application.
19. The guideline should provide advice and/or tools on how the recommendations can be put into practice.

20. The potential resource implications of applying the recommendations should be considered.

21. The guideline should present monitoring and/or audit criteria.

**Editorial independence**

22. The views of the funding body should not influence the content of the guideline.

23. Competing interest of guideline development members should be recorded and addressed.
Appendix 2 Standards of Care Committee Constitution

1. TERMS OF REFERENCE

1.1 The BTS Standards of Care Committee currently has three major responsibilities:

- Primarily, Guideline development. This involves the development and maintenance of robust systems for the production of the Society’s own Guidelines, from assessing the need for a Guideline to the submission for publication, in line with NHS Evidence Accreditation criteria. The scope of this work will involve Guidelines on specific diseases, specific procedures and on processes of care, plus advice about key messages for dissemination, associated audit tool(s) and patient information.

- Production of Quality Standards, based on BTS Guidelines, which aim to provide clinicians, commissioners, planners and patients with a guide to the standards of care that patients with a particular disease/condition should expect, together with measurable markers of good practice.

- Production of Clinical Statements, which will be commissioned by the Committee and produced according to the agreed procedures.

Additionally the Committee will identify research questions arising from Guideline development work and refer these directly to the NIHR Respiratory Specialty Group.

2. MEMBERSHIP

2.1 The membership of the Committee comprises:

- Chair
- Chair-elect (in the third year of the Chair’s period of service, to allow handover)
- Council member(s), who may select to serve on the Committee while serving on Council. A maximum of 4 Council members to be on this Committee at any one time
- Three Consultant physicians who will be selected from those who come forward following the annual call for volunteers (in succession-one per year)
- Three Specialist Trainees who will be selected from those who come forward following the annual call for volunteers (in succession-one per year). One of these will serve additionally on the BTS Specialist Trainees Advisory Group (STAG) and will act as the link between the two
- Two Respiratory Nurse Specialists
- A lay member
- Two representatives from the British Paediatric Respiratory Society (BPRS)
- A representative from the Association of Chartered Physiotherapists in Respiratory Care (ACPRC)
- The Chair of the BTS Board, and Chief Executive, ex-officio (standing invitations, although will not usually attend).

(NB: The Committee cannot have its own Deputy, Honorary Secretary or any other nominal post)

2.2 All members, however selected and in whatever capacity, will normally serve for a maximum of 3 years from the date of taking up membership. The term of service is usually effective from the date of the
Society’s Annual General Meeting each year. The only exception is the Chair – elect. S/he will be appointed in the third year of the Chair’s period of service, to allow handover, and will therefore expect to serve for no longer than 4 years, but exceptionally for 5 or 6 years. This will only occur if the Chair-elect is already serving on the Committee at the time of the election (see Item 3.6 below).

2.3 Members can join Committees in one of 3 ways:

- By volunteering annually in response to a call for volunteers. This is circulated in the early summer each year to all BTS members. The call for volunteers will clearly state the vacancies that are available; the experience and special interests sought (if any) and the arrangements for selection. If there are more volunteers than places available, selection will be undertaken by the Chair of the Committee and Honorary Secretary supported by the Chief Executive or Deputy Chief Executive, based on the provision by volunteers of a short CV and supporting statement.

- When elected to serve on Council, each Council member is asked to select a Standing Committee on which to serve. There is generally no barrier to a Council member joining their Committee of choice, although it may from time to time be necessary to negotiate filling a gap where one exists and the Society has need of additional Council input, and therefore first choice of Committee cannot always be guaranteed.

- By being the nominated representative of one of the bodies mentioned above in the membership list. In this event, the “three year rule” will still apply.

2.4 All members of BTS Committees must be members of the Society unless they have been nominated by an external organisation.

2.5 If a Specialty Trainee sitting on a Committee becomes a Consultant during their period of service, he or she may remain on the Committee for the remainder of their 3 year appointment. However, when their period of office ends they will not be replaced by another Consultant – this will prevent an upward drift in numbers. In the interim another Trainee can be appointed for a three year period at the next annual replacement process so that all Committees have continuous Trainee input.

2.6 If a Committee wishes to involve a member with specific skills, and that person is not therefore likely to be a BTS member; or, if a Committee wishes to vary the membership as 3 outlined above, this MUST be discussed first by the Chair with the BTS Board of Trustees, and agreement of Trustees obtained.

2.7 Every effort is taken to agree dates of meetings one year in advance and notify these to all members as soon as they have been agreed. Dates agreed in advance will only be changed if there are exceptional circumstances, and then at least 8 weeks’ notice will normally be given. If a member misses more than 2 meetings in succession, and there are no extenuating circumstances (in relation to sickness absence, for example), then the Society will ask that member to stand down.

2.8 All members are required to conduct themselves in accordance to the Society’s policies and general procedures (e.g. for travel expenses), and in particular in relation to the policy about relationships with the bio-medical and tobacco industries, and the associated Declarations of Interest Scheme (DoI) (see section 4, following). Members are especially asked to note that efforts should be made to return a completed DoI form before the end of January each year, or prior to the first meeting of the Committee in every calendar year, whichever is earlier. If a form has not been completed after a reminder has been given at that meeting, the member concerned will be asked to withdraw until the information has been provided.

2.9 Chairs and members of all BTS Committees, Advisory Groups, sub-Committees and groups which produce BTS Guidelines and other publications should not accept any invitations from bio-medical industry to attend Advisory Boards or other meetings at which they are described as, and/or referred to, as representing BTS in any way. Nor should they solicit invitations in that capacity. It is up to
individuals to decide whether to accept an invitation to attend such events, but this will be in an individual capacity only and should be declared under the provisions of the Society’s Policy on relationships with the bio-medical industry, through the Declaration of Interests Scheme. If an individual feels any conflict has arisen, they should resign from their BTS position, or the activity in question with immediate effect.

3. **STANDING ORDERS**

3.1 **Role of the Chair of the Committee**
The Chair of the Committee also serves as a Trustee of the Society during the time s/he is in post. S/he is therefore the main link between the development and execution of the Society’s strategic objectives (as summarised in the Strategic Plan) and the detailed work of the Committee.

3.2 The Chair is responsible for the direction, conduct, moving forward and completion of Committee business, both during Committee meetings and between the meetings. In this task s/he is supported by the Society’s staff (who provide a full secretariat service) and other members. A Deputy Chair post is not required and will not be approved.

3.3 The Chair will approve the Committee agenda and draft minutes, which are prepared by BTS staff. S/he will also prepare and/or commission papers from others and will chair the formal meetings of the Committee and any ad-hoc meetings and teleconferences.

3.4 While BTS staff can draft follow up correspondence and deal with queries arising from the work of the Committee on an operational level from day to day, it is anticipated that the Chair will provide advice on content and professional issues involved and, in particular, deal with peers and external organisations in relation to all areas where clinical leadership is required.

3.5 The Chair has an important role in ensuring that Declaration of Interest forms from all Committee members are scrutinised and any issue of concern discussed with the individual concerned and/or the Honorary Secretary. S/he must also ensure that at the beginning of each meeting members are asked to declare any additional recently acquired interests, and is expected to exercise judgement in the conduct of Committee business in the event of any potential conflicts of interest.

3.6 Succession planning for the Chair of the Committee will take place as follows. In the spring of the year when the Chair’s 3-year term in office is due to end, the Society will advertise that a vacancy for the Chair of that Committee will be coming up. A job description will be available. Members of the Committee plus any other member of the Society will be invited to apply. All applicants will be required to send a short CV and a statement outlining why they are interested in the position and what they feel they can bring to the post. Applicants will be shortlisted (if necessary) and interviewed by two of the five Officers (one of which will usually be the Honorary Secretary), supported by the Chief Executive or Deputy Chief Executive. The panel’s decision will be shared with the Officers’ Group for ratification and made known to the successful candidate so that the Chair-elect can spend the remainder of the year before taking up post shadowing the incumbent and receiving information and training about being a Trustee of the Society. The appointment will also be reported to the next scheduled meeting of the Board of Trustees.

3.7 Before a Chair is appointed, s/he will be asked to submit an updated Declaration of Interest form, if this is not already available. This will be submitted to the Chair of the Board of Trustees and Honorary Secretary for approval before the appointment is confirmed.

3.8 **Frequency and conduct of meetings of the Committee**
The Committee will normally meet no more than four times a year, at the Society’s headquarters building in London.
3.9 Trustees recognise that it may be necessary from time to time to plan an additional meeting in any year when anticipated business demands this. This would not normally be a problem, except that short notice may result in poor attendance, and it is important to give at least 8 weeks’ notice. For urgent/timing dependent issues that might arise which do not justify a full agenda, the Society’s constitution allows business to be conducted by teleconference. This can be organised at no cost to Committee members or their employers. This paragraph does not contradict the restriction in Item 2.7 above)

3.10 Because some members have to travel some distance to attend meetings in London, and to maximise the amount of business that can be achieved and also opportunities for “off peak” travel (in at least the return portion) meetings are normally held between 10.30am and 3.00pm and lunch is provided.

3.11 It is not usually acceptable to conduct a Committee meeting at BTS headquarters with one or more members attending for all or part of the meeting via teleconference or web-cam, as this impedes progress of business. The Society recognises that in exceptional circumstances it may be necessary for a Committee member to participate for specific items of business, but this should be arranged on a case-by-case basis.

3.12 The Committee secretary (BTS staff member) will draft an agenda and discuss with the Chair no later than 3 weeks before the date of the meeting. The agenda and papers will be circulated to all members no later than 7 days (and preferably) 10 days before the meeting takes place. It is not good practice, and will not normally be possible, to table papers at meetings, especially those that contain detailed information except at the discretion of the Chair and taking into account circumstances involved. Authors of papers are therefore asked to submit in time according to the date given by the secretariat.

3.13 A draft minute, including named action points, will normally be produced within 7-10 days of the meeting to be agreed by the Chair and then sent to members as an aide-memoire for those who may have been asked to carry out actions, or for the information of those who were not able to attend.

3.14 The nature of the work of this Committee requires that individual members may be called upon to review documentation and provide comments in advance of Committee meetings or in between meetings. Guidance on the work required is provided and the workload shared across the Committee as equitably as possible.

3.15 **Sub-Committees and ad-hoc groups**
Because the Society has a comprehensive network of Specialist Advisory Groups which act as expert advisors in specific disease/therapy areas, it is not generally permitted for Standing Committees to establish any sub-Committees and/or working parties and ad-hoc groupings. Any proposals that this ruling is relaxed must be discussed and agreed by the Board in advance.

4. **CODE OF CONDUCT**

4.1 The Society values the contribution of those members who serve on its various Committees and Advisory Groups and Working Parties. Without this service, it would not be possible to carry out the great variety of work that is undertaken which contributes to the raising of standards of care of people with respiratory disease. BTS has a justifiably high reputation for the quality of its activities and the advice it gives to external bodies.

4.2 The Society is also proud to have been a pioneer in a number of areas, including its Declarations of Interest scheme, which has been replicated by a number of other Societies in recent years. The probity of our actions is underpinned by a number of policies and procedures which are kept under regular (annual) review.
4.3 To ensure effective functioning of the Declarations of Interest process the Chair should proactively manage declarations from SAG members. This will include:

- Having declarations of interest as a standing item on all meeting agendas
- Formally asking members whether anything has changed since they submitted their last declaration
- Formally asking members at the start of each meeting whether there are any agenda items which may cause conflict or in which they have an interest
- Seeking advice when required from the Honorary Secretary or Chief Executive if there are any concerns about new items mentioned under declaration of interest

4.4 Consequently, we ask all members of Committees, Advisory Groups and Working Parties to note and abide by the following policy and procedures documents:

- **BTS Policy on Biomedical Industries & Commercial Sponsorship and associated Declarations of Interest Scheme.** This is reviewed annually by BTS Council and Trustees.
- **Endorsement Policy** (reviewed in January 2017)
- **Complaints procedure** (January 2018)
- **Media policy** (reviewed in November 2016)
- **Travel and subsistence policy** (reviewed annually by Honorary Treasurer and Chief Executive)

Date of production/revision: March 2018
By: Chief Executive
Review date: March 2021

This document is available from the BTS website at: https://www.brit-thoracic.org.uk/media/70432/soc-constitution-march-2018.pdf
Appendix 3 BTS Guidelines – Topic Proposals

The British Thoracic Society has been at the forefront of the production of guidelines for best clinical practice in respiratory medicine since the Society was established over 25 years ago.

The BTS Standards of Care Committee (SOCC) oversees the Society’s guideline production strategy and procedures, including the approval of new guideline topics.

The production of a BTS guideline is a substantial undertaking, requiring significant time and commitment from the guideline group chair and members, as well as BTS Head Office and the Standards of Care Committee members. Details of the guideline production process are available in the BTS Guideline Manual: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/

The SOCC will consider the following factors in the approval process for a new guideline – please address these points in the topic proposal form.

- Are there areas of clinical uncertainty as evidenced by wide variation in practice or outcomes?
- Is this a condition where effective treatment is proven and where mortality or morbidity can be reduced?
- Is this a clinical priority area for BTS where clinical guidance is lacking (and with a perceived need for guidance) and the area is unlikely to be produced by other Guideline producers (such as NICE)?

Each proposal should have the support of a BTS Specialist Advisory Group (SAG), if a relevant group exists.

Please note that BTS is not seeking formal nominations for potential Chairs and Guideline Group members but suggestions for individuals with a particular interest in the proposed topic are welcome.

Topic proposal form available from BTS Head Office.

BTS 2018
Appendix 4 Information on BTS Guidelines

The Society currently lists all published BTS guidelines on the BTS website at: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/

The summary tables (BTS Guidelines, Other Guidance and Guideline Archive), with publication date and status, reflects the need to present this information to underpin the Society’s NICE accreditation.

BTS Guidelines are currently listed on the BTS website with a classification that marks each Guideline as:
- Valid
- In Preparation
- In Consultation
- Archived
- Superseded
- Withdrawn

A new category of ‘Archived’ was introduced in 2017 to indicate Guidelines that are more than 5 years old and where the content as not been checked/reviewed.

Guidelines marked as ‘Withdrawn/Superseded’ are still listed on the BTS website (on individual Guideline pages), but no longer appear in the BTS Guidelines summary table (see below).

BTS Guidelines summary table

The top table on the main BTS Guideline web page (https://www.brit-thoracic.org.uk/quality-improvement/guidelines/) includes:

- Current BTS Guidelines; and
- BTS Guidelines in development (BTS Guidelines that are currently ‘In preparation’)

Other Guidance summary table

This table provides links to ‘Other Guidance’ on particular issues, or disease areas. This includes links to BTS Recommendations, BTS Statements, BTS Clinical Statements and guidelines produced by other organisations (e.g. NICE), which are provided without endorsement.

Guideline Archive summary table

Guidelines that have been published more than five years ago should be moved to the archive section. In each case a brief explanatory statement will be associated with the Guideline, which may include links to more recent guidance, or a statement to say that the Guideline is provided for reference. This means that the list of BTS guidelines is current and that any Guidelines older than five years can still be found in the archive.

The status of “Under review” has now been removed. When using GRADE methodology, an existing Guideline cannot be updated without re-visiting the scope and clinical questions and hence all requested updates will now be considered as new topic proposals.
A disclaimer is added to each ‘Archived’ Guideline page:

_BTS Guidelines published more than five years ago are marked as archived. The Guideline content/recommendations have not been checked to confirm continued validity at the date of archival and readers should bear in mind that new evidence may have been published since the Guideline was produced._

The disclaimer should make it clear that Guidelines will not automatically be updated after five years. Should the chair(s) of an existing Guideline wish to apply to update the Guideline, they should apply in the same way as those submitting a new topic proposal and identify the new scope and clinical questions according BTS GRADE methodology. BTS SAGs may also be a useful source of information should new literature be published in a certain area. It is not expected that Guideline chairs should undertake a top level literature reviews after 3-5 years.

**Links to Guidelines from other organisations**

Archived Guidelines will include clear signposting to relevant guidance from other organisations (primarily NICE and ERS), which have superseded older BTS publications. This will provide useful links to other Guidelines that may be relevant to a given topic, but a clear statement will be included to confirm that inclusion does not constitute BTS endorsement.

**New Guideline proposals**

With the move to GRADE methodology, any new Guideline topic commissioned by BTS will need an updated scope and set of clinical questions, regardless of whether a Guideline on that topic has been published in the past.

This supports the arrangement to mark published Guidelines as ‘Archived’ after a given period and no update to the Guideline is undertaken. A new Guideline may be commissioned on the same, or related topics, but the scope and clinical questions will be new (see _Appendix 3 BTS Guidelines – Topic Proposals_).

**Exceptional Review of selected Guidelines**

There may be instances where certain Guidelines need to be checked and subsequently marked as ‘Valid’ so that they appear Current Guideline listing. The SOCC will advise on these each year as the need arises and a review/check will be done to provide advice on whether the recommendations remain valid. It is likely that this will be required only where a strategic need for review of a topic has been identified as part of the Society’s QI strategy and framework.
Appendix 5 Role Description: Guideline Development Group co-chairs and members

The British Thoracic Society has been at the forefront of the production of Guidelines for best clinical practice in respiratory medicine since the Society was established over 30 years ago.

BTS Guidelines are produced by multidisciplinary groups drawn from those working in respiratory medicine, and allied specialties and professions, and are aimed at providing pragmatic evidence-based guidance for the management of respiratory conditions.

The co-chairs of a Guideline Development Group (GDG) play a critical role in the development of the Guideline and have a key responsibility in ensuring that the guideline production process is conducted appropriately to an agreed timetable.

The co-chairs would be expected to:

• Lead the Guideline development group with support from BTS
• Facilitate the process of the development within the framework of agreed BTS methodology following the AGREE criteria
• Ensure equality of input from all GDG members
• Manage declarations of interest and potential conflicts of interest
• Keep to the scope – manage the ambition of the GDG (noting that this is not a textbook)
• Attend all committee meetings and read meeting papers in advance of meetings.
• Encourage constructive debate among all group members during meetings.
• Participate in guideline development training as appropriate.
• Work with BTS Head office staff and group members as required during and between meetings to identify key issues, formulate clinical questions for review, review evidence tables, and draft recommendations.
• Lead the write up of the draft document (in line with BTS template)
• Work with group members and BTS Head Office staff to write and edit drafts of the guideline.
• Lead the group in considering and addressing stakeholder comments on the draft guideline.
• Provide progress reports to the BTS SOCC as required
• Attend an agreed SOCC meeting to present the draft guideline.
• Support the dissemination and implementation of the Guideline - be a champion for the Guideline after publication and undertake activities to promote its implementation, such as talking at professional conferences and participation in the production of publishing Guideline-related articles in accordance with BTS policy

Guideline Group members would be expected to:

• Participate fully in the work of the GDG with support from BTS
• Adhere to the process of the development within the framework of agreed BTS methodology following the AGREE criteria
• Submit and update declarations of interest and potential conflicts of interest on a regular basis
• Participate in Guideline development training as appropriate
• Attend all committee meetings and read meeting papers in advance of meetings.
• Use their clinical expertise, research evidence and patient wishes to support the Guideline development.
• Input positively in meetings treating all as equals
• Work with BTS Head Office staff, and other group members as required, during and between meetings to produce clinical questions for review, review evidence tables and draft recommendations
• Participate in the preparation and review of the draft document
• Work with the co-chairs, other group members and BTS Head Office staff to write and edit draft sections of the Guideline
• Work with other group members to consider and address stakeholder comments on the draft Guideline
• Support the dissemination and implementation of the Guideline - be a champion for the Guideline after publication and undertake activities to promote its implementation, such as talking at professional conferences and participation in the production of publishing Guideline-related articles in accordance with BTS policy

Declarations of Interest

The co-chairs of the proposed group must complete a BTS Declaration of Interest (DoI) form and any potential conflicts of interest considered by the BTS Honorary Secretary and the Chair of the SOCC before work on the Guideline is undertaken.

The Chair of the SOCC and the co-chairs of the GDG have responsibility for scrutinising Declarations submitted by GDG members.

It is a requirement that Guideline group co-chairs would not have conflicts/declarations of interest in the subject area of the Guideline concerned. It is also expected that at least 50% of the members of a Guideline group would have no declarations/conflicts of interest.

Training

Where possible the co-chairs of the GDG should receive training in advance of the other members of the Group. This may take the form of one or more individual sessions with the BTS SOCC Chair and BTS Head Office team.

Guideline authorship

The co-chairs have responsibility for drafting the scope and agreement will be reached by the full GDG. The co-chairs would take the lead in production of the full draft document for review by the group.

While it is expected that all GDG members would usually be named as authors (and would contribute appropriately to the authorship of the Guideline – fulfilling the stated criteria for authorship as appears on the Thorax website) it is expected that the co-chairs of the Guideline group would be the first named author(s).

The expectations and requirements for all GDG members to contribute as authors to the Guideline should be made clear at the first meeting of the Guideline group.
Appendix 6 GRADE – relative importance of outcomes

Figure 1: GRADE ranking of outcomes

<table>
<thead>
<tr>
<th>rating scale:</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>of least</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>importance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Of limited</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>importance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for making a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>decision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(not included</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in evidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>profile)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important, but</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>not critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for making a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>decision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(included in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>evidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>profile)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for making a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>decision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(included in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>evidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>profile)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2: Examples of GRADE-ranked outcomes

- Mortality 9 Critical
- Hospital admission 8 Important, but not critical
- Pneumonia 7 Critical
- Neurological complications 6 Important, but not critical
- Nausea 2 Of low importance

Figure 1 is taken from, and Figure 2 is adapted from, ‘Section 3.1 Steps for considering the relative importance of outcomes’ of the GRADE Handbook (https://gdt.gradepro.org/app/handbook/handbook.html).

GDGs should list all PICO outcomes and rank by their relative importance (see Figure 1 above), to determine if an outcome is ‘Critical’, ‘Important’, or ‘Important, but not critical’ (Figure 2 provides examples of GRADE-ranked outcomes). All outcomes should be patient focussed and only outcomes deemed as ‘Critical’ or ‘Important’ should be considered for the Guideline. It is recommended that GDGs use a maximum of four outcomes for each PICO question.
## BTS Guideline Protocol Template

<table>
<thead>
<tr>
<th>Field</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review Question</td>
<td>PICO question</td>
</tr>
<tr>
<td>Type of review question</td>
<td>Intervention</td>
</tr>
<tr>
<td>Objective of the review</td>
<td>Give background to the review question – what does the review aim to answer, what might the recommendations cover?</td>
</tr>
<tr>
<td>Eligibility criteria – population / disease / condition / issue / domain</td>
<td>e.g. Adults (16 years and older) with asthma</td>
</tr>
<tr>
<td>Eligibility criteria – intervention(s)</td>
<td>What is / are your intervention(s)?</td>
</tr>
<tr>
<td>Eligibility criteria – comparators(s)</td>
<td>What is / are your comparator(s)?</td>
</tr>
<tr>
<td>Outcomes and prioritisation</td>
<td>CRITICAL: e.g. mortality</td>
</tr>
<tr>
<td></td>
<td>IMPORTANT: e.g. disease progression</td>
</tr>
<tr>
<td>Eligibility criteria – study design</td>
<td>e.g. Randomised controlled trials, systematic reviews of randomised controlled trials</td>
</tr>
<tr>
<td>Other inclusion / exclusion criteria</td>
<td>Non-English language</td>
</tr>
<tr>
<td></td>
<td>Cross-over randomised controlled trials</td>
</tr>
<tr>
<td></td>
<td>Studies comparing combinations of the interventions</td>
</tr>
<tr>
<td>Proposed sensitivity / subgroup analysis, or meta-regression</td>
<td>Subgroups: e.g. children</td>
</tr>
<tr>
<td>Selection process – duplicate screening / selection / analysis</td>
<td>If used, describe methods for duplicate screening, study selection or data extraction. What are thresholds for agreement and mechanisms to resolve disputes?</td>
</tr>
<tr>
<td>Data management (software)</td>
<td>RevMan: Pairwise meta-analyses</td>
</tr>
<tr>
<td></td>
<td>Evidence review/considered judgement</td>
</tr>
<tr>
<td></td>
<td>GRADEpro: Quality of evidence assessment for each outcome</td>
</tr>
<tr>
<td></td>
<td>Endnote: Reference management</td>
</tr>
<tr>
<td>Information sources – databases and dates</td>
<td>Sources to be searched, limits applied to search, supplemental search techniques and rational. Other sources of evidence. Key papers if known.</td>
</tr>
<tr>
<td></td>
<td>Cut-off dates?</td>
</tr>
<tr>
<td>Methods for assessing bias at outcome / study level</td>
<td>RevMan5 used to critically appraise individual studies.</td>
</tr>
<tr>
<td></td>
<td>GRADEprofiler used to evaluate risk of bias across all available evidence.</td>
</tr>
<tr>
<td></td>
<td>Document deviations/alternative approach if GRADE is not used, or if a modified GRADE approach has been used for non-intervention or non-comparative studies</td>
</tr>
<tr>
<td>Methods for quantitative analysis – combining studies and exploring (in)consistency</td>
<td></td>
</tr>
<tr>
<td>Meta-bias assessment – publication bias, selective reporting bias</td>
<td></td>
</tr>
<tr>
<td>Rationale / context – what is known</td>
<td></td>
</tr>
</tbody>
</table>

August 2018
Appendix 8 Literature search and literature management

Support for literature searches
BTS has an agreement with the Centre for Reviews and Dissemination (CRD), University of York for assistance with the development of search strategies, literature searches, the provision of lists of abstracts as well as acquisition of papers. BTS Head Office will provide support for the conduct of the literature search and provide the link to the team in York. Further details of the services provided are available from BTS Head Office.

Managing data
The CRD will provide the results of literature searches as Endnote files (Endnote is a reference management software programme). The results of the searches (references and abstracts) can be exported into Excel or Word from Endnote for checking by GDG members. BTS will hold the master copy of the Endnote file for referencing the Guideline document at final draft stage.

Obtaining copies of papers
GDG members will sift through abstracts provided by the literature searches and will generate a list of references for which the full papers are required. Copies of papers may be obtained from:

- Journals/books held as personal copies by GDG members
- Individual members’ institutional library (or electronic library) subscriptions, e.g. via NHS or university Athens accounts.

BTS Head Office can assist where journal articles are particular difficult to locate.
### Effect of long-term, low-dose macrolides on COPD patients for COPD

**Patient or population:** patients with COPD  
**Settings:**  
**Intervention:** Effect of long-term, low-dose macrolides on COPD patients

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong></td>
<td>Moderate 3 per 100 2 per 100 (2 to 3)</td>
<td>RR 0.78 (0.58 to 1.06)</td>
<td>12468 (4 studies)</td>
<td>low²</td>
<td></td>
</tr>
<tr>
<td><strong>Hospital Admissions - any cause</strong></td>
<td>Moderate 16 per 100 14 per 100 (11 to 17)</td>
<td>RR 0.85 (0.88 to 1.07)</td>
<td>2863 (4 studies)</td>
<td>moderate³</td>
<td></td>
</tr>
<tr>
<td><strong>Hospital Admissions - COPD</strong></td>
<td>Moderate 7 per 100 7 per 100 (4 to 10)</td>
<td>RR 0.92 (0.6 to 1.42)</td>
<td>2459 (4 studies)</td>
<td>moderate³</td>
<td></td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  

**CI:** Confidence interval, **RR:** Risk ratio  
**GRADE Working Group grades of evidence**  
**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality:** We are very uncertain about the estimate.

1 Study design varies between studies.  
2 RRR crosses 25%.  
3 RR crosses ±25%.
# Appendix 10 GRADEpro recommendations

**QUESTION**

<table>
<thead>
<tr>
<th>POPULATION:</th>
<th>COPD patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERVENTION:</td>
<td>Long-term, low-dose macrolides on vs. standard care</td>
</tr>
<tr>
<td>COMPARISON:</td>
<td>standard care</td>
</tr>
<tr>
<td>MAIN OUTCOME:</td>
<td>Mortality;</td>
</tr>
<tr>
<td>SETTING:</td>
<td></td>
</tr>
<tr>
<td>PERSPECTIVE:</td>
<td></td>
</tr>
<tr>
<td>BACKGROUND:</td>
<td></td>
</tr>
<tr>
<td>CONFLICT OF INTERESTS:</td>
<td></td>
</tr>
</tbody>
</table>

## ASSESSMENT

### Problem

<table>
<thead>
<tr>
<th>JUDGMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Probability no</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Probability yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Don't know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Desirable Effects

How substantial are the desirable anticipated effects?

<table>
<thead>
<tr>
<th>JUDGMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Trivial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Small</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Don't know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Long-term treatment with macrolides has been associated with several adverse effects (43). The most common side effects relate to the gastrointestinal tract by stimulating gastrointestinal motility through motilin-like activity. Symptoms including anorexia, nausea, vomiting, diarrhoea and abdominal pain were reported in COPD patients in the studies reviewed. Cessation of treatment due to gastrointestinal side effects were reported in the studies published by Banerjee, Suzuki, Seemungal, He and Basi (14-18). Ursan published side-effect profiles, indicating that diarrhoea was the only event that was higher statistically significantly more frequent in the Azithromycin group compared with placebo (11).

### Undesirable Effects

How substantial are the undesirable anticipated effects?

<table>
<thead>
<tr>
<th>JUDGMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Large</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Small</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Trivial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Don't know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Long-term treatment with macrolides has been associated with several adverse effects (43). The most common side effects relate to the gastrointestinal tract by stimulating gastrointestinal motility through motilin-like activity. Symptoms including anorexia, nausea, vomiting, diarrhoea and abdominal pain were reported in COPD patients in the studies reviewed. Cessation of treatment due to gastrointestinal side effects were reported in the studies published by Banerjee, Suzuki, Seemungal, He and Basi (14-18). Ursan published side-effect profiles, indicating that diarrhoea was the only event that was higher statistically significantly more frequent in the Azithromycin group compared with placebo (11).

### Certainty of evidence

What is the overall certainty of the evidence of effects?

<table>
<thead>
<tr>
<th>JUDGMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Very low</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Low</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- No included studies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SUMMARY OF JUDGEMENTS

<table>
<thead>
<tr>
<th>PROBLEM</th>
<th>JUDGEMENT</th>
<th>VALUES</th>
<th>BALANCE OF EFFECTS</th>
<th>ACCEPTABILITY</th>
<th>FEASIBILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Probably no</td>
<td>Important uncertainty or variability</td>
<td>Favors the comparison</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
<td>Varies</td>
<td>Probably important uncertainty or variability</td>
<td>Probably favors the comparison</td>
<td>Probably yes</td>
<td>Probability yes</td>
</tr>
<tr>
<td>Varies</td>
<td>Don’t know</td>
<td>No important uncertainty or variability</td>
<td>Does not favor either the intervention or the comparison</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>Don’t know</td>
<td>Varies</td>
<td>No included studies</td>
<td>Favor the intervention</td>
<td>Don’t know</td>
<td>Don’t know</td>
</tr>
</tbody>
</table>

### TYPE OF RECOMMENDATION

<table>
<thead>
<tr>
<th>Strong recommendation against the intervention</th>
<th>Conditional recommendation against the intervention</th>
<th>Conditional recommendation for either the intervention or the comparison</th>
<th>Conditional recommendation for the intervention</th>
<th>Strong recommendation for the intervention</th>
</tr>
</thead>
</table>

### CONCLUSIONS

**Recommendation**

**Justification**

**Subgroup considerations**

**Implementation considerations**

**Monitoring and evaluation**

**Research priorities**
Appendix 11 BTS Guideline Support for Judgement Template

[TITLE]

Introduction

Provide background on the PICO question – potential questions to address:

i) Description of the condition
ii) Description of the intervention
iii) How might the intervention work?
iv) Why it this important?

Outcomes

What are the PICO outcomes you are investigating?

Evidence Review

This is the main body of your literature review and evidence. Questions you should be asking:

i) Types of studies you are reviewing
   a. Which studies have you included?
   b. Have you excluded studies? Why?

ii) Types of participants
   a. Do they match your PICO question?

iii) Types of interventions
   a. Do the data interventions differ from your PICO intervention(s)?

iv) Types of outcome measures
   a. Are the outcomes different to your PICO outcomes?
   b. Are the data primary outcomes or secondary outcomes?

v) What are the effects of the interventions?
   a. Address each PICO outcome individually and review the literature per outcome.

vi) Side effects, mortality, etc.?

Evidence Statements

This section should consist of a set of statements (one per outcome) summarising the effect of the intervention against the comparison within the population (i.e. based on your PICO questions and outcomes) and include the GRADE quality of evidence score for each statement (High, Moderate or Low), e.g. Long term macrolide antibiotics are effective in reducing the acute exacerbation rate in patients with COPD with high exacerbation rates (i.e. three or more exacerbations per year). (High)

Recommendations

Good Practice Points

Research Recommendations

The above three sections should be based on the output of the GRADE recommendations.
Appendix 12 Supporting information

Each Guideline should include the following information which may be most appropriately included as web-based appendices to the published document:

Summary of recommendations
Each Guideline document will include a summary of the recommendations at the start of the Guideline supplement.

Accompanying Thorax highlights article
A separate (short – 1500 word) article is usually produced by one, or more, Guideline Development Group (GDG) members following completion of the main Guideline document and submitted to Thorax (via BTS Head Office). This article summarises the main points of the Guideline and is published in the main Thorax journal to accompany publication of the Guideline supplement.

Patient Information
GDGs should provide examples of patient information leaflets as appropriate to the topic of the Guideline, where these are not provided by other patient groups, or lung charities. BTS Head Office will provide advice in relation to the development of patient information.

Education materials
The GDG will be asked to develop educational materials to assist with the dissemination and implementation of the Guideline recommendations. Educational materials may be produced in one or more of the following formats:

- As the topic of a session at the BTS Summer or Winter Meeting following (or just prior to) Guideline publication
- As the subject of a BTS Short Course
- As the subject for the development of a module as part of the BTS Learning Hub
- As a series of supplementary documents or PowerPoint files made available to accompany the published Guideline

BTS Head Office will provide advice and assistance for the production of this supporting material.

Research recommendations
As part of the Guideline production process, GDGs should provide a list of recommendations for further research. Research recommendations can be provided as an appendix to the main Guideline and will be passed to the BTS Science and Research Committee following publication of the Guideline.
Appendix 13 BTS Quality Standards and Audits

Quality Standards

A Quality Standard is a set of specific, concise statements that:

- Act as markers of high quality, cost-effective patient care across a pathway or clinical area, covering treatment or prevention
- Are derived from the best available evidence and are produced collaboratively with the NHS along with their partners and service users

A Quality Standards statement is a key part of the range of supporting materials that the Society produces to assist in the implementation of Guideline recommendations; and the Society aims to produce a Quality Standards document based on the recommendations of each BTS Guideline.

The production of BTS Quality Standards is overseen by the Standards of Care Committee.

BTS Quality Standards are published in the BMJ Open Respiratory Research (since 2017) and are available from the BTS website (https://www.brit-thoracic.org.uk/quality-improvement/quality-standards/)

Audits

Currently, the BTS audit programme offers 11 national clinical audits, covering both adult and paediatric respiratory disease. It is suggested that all Guidelines include a listed of suggested audit criteria. Audits to be offered via the BTS audit system are usually produced following the publication of an appropriate Quality Standard document, but it is good practice to include audit points for local use in the Guideline document.

March 2018
Appendix 14 BTS Guidelines and *Thorax*: Production Process

**Introduction**
BTS Guidelines are usually published as supplements to the journal *Thorax*. This document sets out the main elements of the process to be followed to ensure that the requirements of the BTS Guideline production process, and the peer review processes of Thorax are met.

BTS Guideline production is accredited by NICE, and the BTS Guideline process is documented in the Guideline manual (available on the BTS website and updated each year: [https://www.brit-thoracic.org.uk/quality-improvement/guidelines/](https://www.brit-thoracic.org.uk/quality-improvement/guidelines/)).

**Guideline preparation**
The BTS Standards of Care Committee (SOCC) oversees the commissioning and approval of Guidelines, and each Guideline is rigorously reviewed by the Committee before approval is given for the public/stakeholder consultation phase.

Following the selection of a Guideline topic, the SOCC will review and approve the scope of the Guideline and the draft clinical questions to be addressed.

The chair (or more usually co-chairs) of the Guideline group are required to make regular progress reports to the SOCC and will also present an early draft to the Committee for preliminary review well before the final draft is presented for approval for the consultation stage.

**Public consultation**
The Standards of Care Committee will review the final draft guideline and make a decision on approval for the public consultation process.

The consultation draft is made available on the BTS website for at least 4 weeks and feedback is invited from stakeholder organisations and the wider BTS membership.

The consultation draft will be uploaded to Scholar One to ensure the manuscript is in the Thorax production process.

At this stage Thorax EICs will be invited to nominate 3 reviewers to provide detailed peer review of the Guideline draft as part of the consultation process. EICs will also involve the appropriate Associate Editor in the selection of reviewers. The duty EIC may assign the manuscript to an associate editor. This will occur when the subject of the Guideline is an area where the sub-specialty expertise of an Associate Editor will be helpful.

The invitation to peer reviewers will be issued via Scholar One. Peer reviewers will be invited to complete their review within the timeframe of the consultation process. The Scholar One process required reviewers to declare any interest related to the paper concerned. The reviews provided by individuals nominated by Thorax editors will constitute the substantive peer review for the guideline. The reviewer comments will be sent to BTS head office (with a note of declared interests) to include in the public consultation feedback.

At the end of the consultation period BTS will:

- Produce a collated copy of comments from all respondents (including Thorax reviewers)
- Send all comments to the Guideline group with a request to address each comment and provide a response and produce an updated (tracked change) Guideline draft.
Submission for publication

Following final approval by the SOCC, BTS will submit the following documents to Thorax via Scholar One:
- Final manuscript – clean
- Consultation copy of manuscript (R0)
- All consultation comments and responses (spreadsheet)
- Tracked change copy of manuscript showing all amendments to draft in relation to consultation comments (including Thorax reviewers) (R1)

On submission of the final clean copy of the manuscript via Scholar One the manuscript will be sent to the duty EIC/ hanging committee for final discussion and comments. At this point minor comments only (format/consistency/style) will be fed back to BTS for attention at either pre-proof or proof stage. No further detailed peer review is required at this stage. The comments provided at this point would be aimed at improving clarity rather than changes to content/substance.

BTS will work with the Thorax production team to check and correct proofs and agree the publication date.

Associated publications

Following acceptance of the Guideline on Scholar one BTS will:
- Arrange for a short “highlights article” to be produced and submitted to Thorax to accompany the publication of the Guideline supplement. This will be reviewed by Thorax editors for publication in the main journal (and should be submitted as an editorial). This document is likely to be authored by one or more members of the Guideline group.
- Submit the summary of the recommendations of the Guideline (with brief introduction) to BMJ Open Respiratory Research, for publication on the BMJORR website to coincide with publication of the main Guideline.

Thorax editors may:
- Commission an editorial from independent authors on the content of the Guideline.

Other BTS publications

BTS has recently introduced a new series of publications “Clinical Statements, one of which has been published in Thorax in 2017 (BTS Clinical Statement on Pulmonary Arteriovenous Malformations).

For those Clinical Statements that may be appropriate for publication in Thorax in future, the Editors will be notified at an early stage in production that the document is in preparation, and the process for review and revision will be conducted as part of the public consultation process and subsequent approval by the SOCC as outlined above.
Future Guidelines and other publications
BTS will ensure that Thorax EIS and the production team are sent an update on Guidelines and clinical statements in progress every 6 months.

Review and approval
This statement was prepared following discussion between BTS Head Office and Thorax Editors on 3 May 2018, building on the previously agreed Guideline production process.

The arrangements were updated in October 2018.
The above arrangements will come into force with immediate effect and be reviewed at the next meeting of the Thorax Management Committee in January 2018.

BTS/S November 2018 v1.1
31 October 2019 v1.2